Filing Flows › United Therapeutics (UTHR) › Free cash flow
United Therapeutics (UTHR) free cash flow by quarter
United Therapeutics' free cash flow was $126M in Q3 2026 (third quarter 2026), -39% from Q2 2026. Over the last 7 quarters it ranged from $126M (Q3 2026) to $386M (Q1 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $126M | -39% | -64% |
| Q2 2026 | $206M | -43% | +59% |
| Q1 2026 | $362M | +109% | -6% |
| Q4 2025 | $173M | -51% | — |
| Q3 2025 | $352M | +172% | — |
| Q2 2025 | $130M | -66% | — |
| Q1 2025 | $386M | — | — |
Q3 2026 at a glance
United Therapeutics, Q3 2026: revenue $832M (+4% year over year), operating margin 37.0%, net earnings $259M, operating cash flow $306M. The chart follows the revenue to costs, profit and cash.
Questions
What is United Therapeutics' free cash flow?
United Therapeutics' free cash flow was $126M in Q3 2026 (third quarter 2026), -39% from Q2 2026.
How has United Therapeutics' free cash flow changed?
Over the last 7 quarters it ranged from $126M (Q3 2026) to $386M (Q1 2025).